AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26867337 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin therapy (1.6 mg subcutaneous injection, qd X 7 d)
Number of subjects: 52
Study 26867337 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (ICU conventional treatment)
Number of subjects: 52
Study 22763798 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation (7 g/day for 1 week)
Number of subjects: 10
Study 22763798 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched healthy controls)
Number of subjects: 10
Study 21971663 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐Ala‐Gln 20% plus saline 750 ml (Group L‐Ala‐Gln, n=11)
Number of subjects: 22
Study 21971663 — intervention group
Group type: COMPARATOR
Intervention: Saline 1000 ml (Group Saline, n=11)
Number of subjects: 22
Study 17512527 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding empowerment programme (4 sessions of 60 minutes each for 4 weeks)
Number of subjects: 60
Study 16709595 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic use
Number of subjects: 1391
Study 16709595 — intervention group
Group type: COMPARATOR
Intervention: No diuretic use
Number of subjects: 1391
Study 15508179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with birch pollen extract
Number of subjects: 74
Study 15508179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with birch pollen extract
Number of subjects: 74
Study 15508179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 11430776 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (‐2929 kJ/d) and drug therapy (or placebo)
Number of subjects: 35
Study 11430776 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (‐2929 kJ/d)
Number of subjects: 35
Study 11430776 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-programme weight stability
Number of subjects: 35
Study 9153530 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 0
Study 9153530 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 0
Study 9153530 — intervention group
Group type: COMPARATOR
Intervention: Control (patients prior to treatment)
Number of subjects: 0
Study 7974898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 7974898 — intervention group
Group type: EXPERIMENTAL
Intervention: Colony-stimulating factor support for chemotherapy
Number of subjects: 0
Study 7974898 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive surgical therapy
Number of subjects: 0
Study 7974898 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer cytotoxic regimens
Number of subjects: 0
Study 2455188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (TC)
Number of subjects: 32
Study 2455188 — intervention group
Group type: COMPARATOR
Intervention: Oral propranolol (OP)
Number of subjects: 32
Study 30677198 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support group (telephone-based peer support)
Number of subjects: 76
Study 30677198 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (routine care and health education measures)
Number of subjects: 76
Study 27693054 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament substituting (PS) total knee arthroplasty
Number of subjects: 100
Study 27693054 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate ligament retaining (CR) total knee arthroplasty
Number of subjects: 100
Study 27693054 — intervention group
Group type: COMPARATOR
Intervention: Both groups (PS and CR)
Number of subjects: 100
Study 25720615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis CD2 lozenges, three times daily for 14 days
Number of subjects: 34
Study 25720615 — intervention group
Group type: COMPARATOR
Intervention: Placebo, three times daily for 14 days
Number of subjects: 34
Study 23877055 — intervention group
Group type: EXPERIMENTAL
Intervention: PortionSize@warenessTool (intervention group)
Number of subjects: 310
Study 23877055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 310
Study 20512394 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO group A (n = 13)
Number of subjects: 40
Study 20512394 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO group B (n = 14)
Number of subjects: 40
Study 20512394 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 40
Study 20512394 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO group A
Number of subjects: 40
Study 20512394 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO group B
Number of subjects: 40
Study 20512394 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 20512394 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO groups (A and B combined)
Number of subjects: 40
Study 18499176 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical varicocelectomy
Number of subjects: 298
Study 18499176 — intervention group
Group type: COMPARATOR
Intervention: Open varicocelectomy
Number of subjects: 298
Study 18499176 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic varicocelectomy
Number of subjects: 298
Study 18499176 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Microsurgical, Open, Laparoscopic)
Number of subjects: 298
Study 16600170 — intervention group
Group type: EXPERIMENTAL
Intervention: Midbrain DNA from PD cases
Number of subjects: 11
Study 16600170 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudate nucleus/putamen DNA from PD cases
Number of subjects: 11
Study 16600170 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamus DNA from PD cases
Number of subjects: 11
Study 16600170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampus DNA from PD cases
Number of subjects: 11
Study 16600170 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA conformation in midbrain, caudate nucleus/putamen, thalamus, and hippocampus in PD
Number of subjects: 11
Study 16600170 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal, temporal, and occipital cortex, and cerebellum DNA from PD cases
Number of subjects: 11
Study 14561542 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 400
Study 10811265 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pentosan polysulphate (CaPPS) 10 mg/kg orally, once weekly for four weeks, repeated every 12 weeks.
Number of subjects: 0
Study 10811265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10811265 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium pentosan polysulphate (CaPPS)
Number of subjects: 0
Study 8781669 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ASA (90 mg/ml)
Number of subjects: 16
Study 8781669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine solution 30 mg/ml)
Number of subjects: 16
Study 1616392 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 325
Study 1616392 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AM)
Number of subjects: 325
Study 1616392 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinine (QN)
Number of subjects: 325
Study 1616392 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (S-P)
Number of subjects: 325
Study 1616392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 15 mg kg-1 (M15)
Number of subjects: 325
Study 1616392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 25 mg kg-1 (M25)
Number of subjects: 325
Study 1616392 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) treatment failures treated with Mefloquine 25 mg kg-1
Number of subjects: 325
Study 6549515 — intervention group
Group type: COMPARATOR
Intervention: Argon laser iridotomy
Number of subjects: 21
Study 6549515 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser iridotomy
Number of subjects: 21
Study 31146656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C patients (mean Tacstd-2 concentration 691.2 ± 473.3 ng/U)
Number of subjects: 61
Study 31146656 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (mean Tacstd-2 concentration 524 ± 290.1 ng/U)
Number of subjects: 61
Study 31146656 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhotic hepatitis C patients
Number of subjects: 61
Study 31146656 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C patients with Tacstd-2 <500 ng/U
Number of subjects: 61
Study 29171829 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid used at academic clinic
Number of subjects: 242
Study 29171829 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid used at community clinic
Number of subjects: 242
Study 29171829 — intervention group
Group type: COMPARATOR
Intervention: Decision aid
Number of subjects: 242
Study 28283148 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone with access to the MOTECH Suite application and a closed user group
Number of subjects: 327
Study 28283148 — intervention group
Group type: COMPARATOR
Intervention: Mobile phone set up on a closed user group but with no application
Number of subjects: 327
Study 28283148 — intervention group
Group type: COMPARATOR
Intervention: No mobile phone but same level of training as the previous 2 groups
Number of subjects: 327
Study 25304187 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal distribution of misoprostol (for self-administration after home birth or when oxytocin is not available)
Number of subjects: 2436
Study 25304187 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2436
Study 22330022 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight management intervention
Number of subjects: 225
Study 22330022 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity at 12 months
Number of subjects: 225
Study 22330022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity at 24 months
Number of subjects: 225
Study 22330022 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 225
Study 19164497 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0
Study 19164497 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid drink (BAL)
Number of subjects: 0
Study 17538513 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir
Number of subjects: 127
Study 17538513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 16235179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted indinavir and efavirenz with stavudine
Number of subjects: 78
Study 16235179 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted indinavir and efavirenz without stavudine
Number of subjects: 78
Study 12377839 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based special intervention (SI; n = 36) for 8 weeks (average session length, 16.3 min)
Number of subjects: 71
Study 10416141 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged second stage of labor (mean: 189 minutes)
Number of subjects: 5241
Study 10416141 — intervention group
Group type: COMPARATOR
Intervention: Short second stage of labor (mean: 19 minutes)
Number of subjects: 5241
Study 8551485 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 120-240 mg once daily for 8 weeks
Number of subjects: 76
Study 8551485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 2272345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 21
Study 2272345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7008821 — intervention group
Group type: EXPERIMENTAL
Intervention: Azatadine maleate (4 mg/day for 1 week)
Number of subjects: 20
Study 7008821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30357660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-one condition
Number of subjects: 0
Study 30357660 — intervention group
Group type: COMPARATOR
Intervention: Pay-all condition
Number of subjects: 0
Study 30103400 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnivore (OM) breakfast
Number of subjects: 32
Study 30103400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-Ovo Vegetarian (LOV) breakfast
Number of subjects: 32
Study 30103400 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan (VE) breakfast
Number of subjects: 32
Study 27333048 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning group
Number of subjects: 332
Study 27333048 — intervention group
Group type: COMPARATOR
Intervention: Non-e-learning group
Number of subjects: 332
Study 25051173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE)
Number of subjects: 19
Study 25051173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study 22002564 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy concurrent with letrozole 2.5 mg (study arm, n = 50)
Number of subjects: 101
Study 22002564 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy alone (control arm, n = 51)
Number of subjects: 101
Study 19307972 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target-controlled infusion based on a weight adjustment formula (group adjusted)
Number of subjects: 24
Study 19307972 — intervention group
Group type: COMPARATOR
Intervention: Propofol target-controlled infusion without adjustment (group total body weight - TBW)
Number of subjects: 24
Study 18004169 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage room
Number of subjects: 398
Study 18004169 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing orders in common obstetric problems
Number of subjects: 398
Study 18004169 — intervention group
Group type: COMPARATOR
Intervention: Standard care labor room
Number of subjects: 398
Study 14993502 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 12 months) and steroids (methylprednisolone pulses 3 x 1 g, i.v. at months 1, 3 and 5, and oral prednisone 0.5 mg/kg/48 h for 6 months)
Number of subjects: 65
Study 14993502 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (not specified treatment)
Number of subjects: 65
Study 12145596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffening device activated
Number of subjects: 175
Study 12145596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stiffening device with magnetic endoscope imaging
Number of subjects: 175
Study 12145596 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-stiffness device overall
Number of subjects: 175
Study 12145596 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stiffening device)
Number of subjects: 175
Study 10413065 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 0
Study 10413065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7587730 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated cell counters (Technicon H*1, TOA NE8000, Coulter STKS, Abbott CD3000)
Number of subjects: 524
Study 7587730 — intervention group
Group type: COMPARATOR
Intervention: Traditional eye count differential
Number of subjects: 524
Study 2239778 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable-protein mixed diet at 96, 128, 160, and 192 mg N.kg body wt‐1.d‐1 for 10 days
Number of subjects: 8
Study 2239778 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-egg protein diet at 160 mg N.kg‐1.d‐1 for 10 days
Number of subjects: 8
Study 2239778 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggested protein recommended allowance
Number of subjects: 8
Study 348260 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 300 mg in a single daily dose
Number of subjects: 16
Study 348260 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 300 mg/day in three doses
Number of subjects: 16
Study 348260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31996259 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interventions
Number of subjects: 5
Study 30515719 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 30515719 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 0
Study 30515719 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 27941119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin, 2 times daily for 7 days
Number of subjects: 849
Study 27941119 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 times daily for 7 days
Number of subjects: 849
Study 27941119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849
Study 27941119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin
Number of subjects: 849
Study 24828121 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging while driving
Number of subjects: 28
Study 24828121 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating while driving
Number of subjects: 28
Study 24828121 — intervention group
Group type: COMPARATOR
Intervention: Drinking 400 mL water
Number of subjects: 28
Study 24828121 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking 400 mL water and eating a 6-inch Subway sandwich
Number of subjects: 28
Study 24828121 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking 400 mL water and composing 3 text messages
Number of subjects: 28
Study 23421352 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 IU intranasal oxytocin for 10 consecutive days
Number of subjects: 41
Study 23421352 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 consecutive days
Number of subjects: 41
Study 21030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% eye drops, 4 times per day for 2 days, plus 2 drops 30 min apart 1 hour prior to surgery
Number of subjects: 97
Study 21030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% eye drops, 4 times per day for 2 days, plus 4 drops 10 min apart 1 hour prior to surgery
Number of subjects: 97
Study 21030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% eye drops, 4 times per day for 2 days, plus 2 drops 30 min apart 1 hour prior to surgery
Number of subjects: 97
Study 21030410 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% eye drops, 4 times per day for 2 days, plus 4 drops 10 min apart 1 hour prior to surgery
Number of subjects: 97
Study 19169446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% solution of CHX
Number of subjects: 10
Study 19169446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% solution of CHX
Number of subjects: 10
Study 19169446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% gel
Number of subjects: 10
Study 19169446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% spray
Number of subjects: 10
Study 19169446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% spray
Number of subjects: 10
Study 19169446 — intervention group
Group type: EXPERIMENTAL
Intervention: swab with 0.2% solution
Number of subjects: 10
Study 15781531 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized flush solution (group H, n = 100)
Number of subjects: 200
Study 15781531 — intervention group
Group type: COMPARATOR
Intervention: Nonheparinized flush solution (group S, n = 100)
Number of subjects: 200
Study 15781531 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized flush solution (group H)
Number of subjects: 200
Study 15781531 — intervention group
Group type: COMPARATOR
Intervention: Nonheparinized flush solution (group S)
Number of subjects: 200
Study 15781531 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 10551070 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration with e‐PTFE membranes supported by stainless steel screws and autologous bone chips (Group 1)
Number of subjects: 30
Study 10551070 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone blocks taken from intraoral or extraoral sites (Group 2)
Number of subjects: 30
Study 8742916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.3 U/min)
Number of subjects: 23
Study 8742916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0.3 U/min) plus nasal oxygen (4 L/min)
Number of subjects: 23
Study 8742916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1655647 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion (50 ng x kg-1 x min-1)
Number of subjects: 14
Study 1655647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6416844 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 39
Study 6416844 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 39
Study 6416844 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine and Propranolol
Number of subjects: 39
Study 29885777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cART vitamin D deficiency
Number of subjects: 270
Study 29885777 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline selenium deficiency
Number of subjects: 270
Study 29885777 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 270
Study 29885777 — intervention group
Group type: EXPERIMENTAL
Intervention: High sCD14
Number of subjects: 270
Study 29924184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates with inspiratory training
Number of subjects: 31
Study 29924184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 27865354 — intervention group
Group type: EXPERIMENTAL
Intervention: 420 IU vitamin D3
Number of subjects: 96
Study 27865354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 25192333 — intervention group
Group type: EXPERIMENTAL
Intervention: NP001 (0.2, 0.8, 1.6, and 3.2 mg/kg, single i.v. dose)
Number of subjects: 32
Study 25192333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 patients)
Number of subjects: 32
Study 22281051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 354
Study 22281051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354